Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB 
Welcome,         Profile    Billing    Logout  
 5 Diseases   20 Trials   20 Trials   1129 News 


«12345678910111213»
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  Utilization of Romosozumab in Primary Care. (Pubmed Central) -  May 24, 2024   
    Primary care physicians should consider romosozumab for patients at high fracture risk who are intolerant or have not responded to other pharmacological treatment. Further studies are needed to clarify the safety of cardiovascular events.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Major Pancreatic Resection Increases Bone Mineral Density Loss, Osteoporosis, and Fractures. (Pubmed Central) -  May 22, 2024   
    After pancreatic resection, patients are at higher risk for BMD loss and subsequent fractures. As the cohort of pancreatic resection survivorship grows, attention will need to be paid to focused prevention efforts to reduce BMD loss, osteoporosis, and fractures in these vulnerable patients, with specific attention to the pancreatic cancer population.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  The use of anabolic agents in the treatment of osteoporosis: a clinical update. (Pubmed Central) -  May 16, 2024   
    No abstract available Integrating anabolic agents into personalized treatment plans has the potential to significantly improve outcomes and quality of life for patients with severe osteoporosis, highlighting the importance of this therapeutic class in the management of this chronic condition.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Trial completion date, Trial primary completion date:  Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta (clinicaltrials.gov) -  May 16, 2024   
    P3,  N=106, Recruiting, 
    Integrating anabolic agents into personalized treatment plans has the potential to significantly improve outcomes and quality of life for patients with severe osteoporosis, highlighting the importance of this therapeutic class in the management of this chronic condition. Trial completion date: Sep 2027 --> May 2027 | Trial primary completion date: Jun 2027 --> Feb 2027
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Cardiovascular Safety and Romosozumab - The Plot Thickens. (Pubmed Central) -  May 8, 2024   
    Trial completion date: Sep 2027 --> May 2027 | Trial primary completion date: Jun 2027 --> Feb 2027 No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Journal:  3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) -  May 2, 2024   
    3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Retrospective data, Journal:  The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. (Pubmed Central) -  Apr 24, 2024   
    In general, at 2?years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site. The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Reconstruction of Remodeling units reveals positive effects after 2 and 12 (Pubmed Central) -  Apr 19, 2024   
    These evolving bone packets may reflect early stimulation of bone formation that contributes to the increase in completed wall thickness at M12. These data suggest that romosozumab induces a positive bone balance due to its effects on bone resorption and formation at the level of the remodeling unit, contributing to the positive effects on bone mass, structure, and fracture risk.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Preclinical, Journal:  Influence of anti-sclerostin monoclonal antibody in the repair of post-extraction sockets of ovariectomized rats. (Pubmed Central) -  Apr 17, 2024   
    These data suggest that romosozumab induces a positive bone balance due to its effects on bone resorption and formation at the level of the remodeling unit, contributing to the positive effects on bone mass, structure, and fracture risk. Scl-Ab-based medication did not accelerate alveolar bone formation but exhibited better post-extraction repair characteristics, and collagen content compared to ovariectomized animals only.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Trial completion date, Trial primary completion date:  A Study of Romosozumab (EVENITY (clinicaltrials.gov) -  Apr 11, 2024   
    P4,  N=100, Recruiting, 
    Scl-Ab-based medication did not accelerate alveolar bone formation but exhibited better post-extraction repair characteristics, and collagen content compared to ovariectomized animals only. Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Feb 2026 --> Nov 2025
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Enrollment closed, Trial completion date, Trial primary completion date:  Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (clinicaltrials.gov) -  Apr 9, 2024   
    P2,  N=36, Active, not recruiting, 
    Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Feb 2026 --> Nov 2025 Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Mar 2027 | Trial primary completion date: Feb 2024 --> Feb 2026
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena. (Pubmed Central) -  Apr 6, 2024   
    In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 "relatively new statements" that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Editorial: Immunological processes in maxillofacial bone pathology. (Pubmed Central) -  Apr 1, 2024   
    Our results suggest that romosozumab stimulates bone growth at the graft site, and similar effects were achieved at 1/10 of the standard dosage. No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. (Pubmed Central) -  Mar 29, 2024   
    Since these two chronic diseases frequently co-exist, there are data suggesting that anti-osteoporosis treatments may affect NAFLD progression by impacting on its pathogenetic mechanisms. In the present review, we present on overview of the current understanding of the liver-bone cross talk and summarize the experimental and clinical evidence correlating NAFLD and osteoporosis, focusing on the possible effects of anti-osteoporotic drugs on NAFLD.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    ROMOSOZUMAB AND DENOSUMAB COMBINATION THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS (Poster Tour 3) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1142;    
    Romosozumab added to ongoing denosumab resulted in an increase in P1nP and lumbar spine BMD, but not in femoral neck BMD. For patients on denosumab, using romosozumab as an additional treatment appeared to be useful in terms of bone formation markers and spine BMD versus denosumab alone.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Enrollment closed:  Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI (clinicaltrials.gov) -  Mar 4, 2024   
    P4,  N=40, Active, not recruiting, 
    In a diverse real-world setting, prescription of romosozumab for osteoporosis is associated with less adverse CV events when compared to PTH analog therapy. Recruiting --> Active, not recruiting
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Metabolic bone diseases : what's new in 2023 (Pubmed Central) -  Feb 1, 2024   
    New meta-analyses confirm the benefits of Vitamin D on fractures and falls. Finally, multiples trials with new molecules for the treatment of rare bone diseases, including osteogenesis imperfecta, fibrous dysplasia and hypoparathyroidism, shown promising results.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature. (Pubmed Central) -  Jan 8, 2024   
    Anabolic and dual-action agents like teriparatide, abaloparatide, and romosozumab have emerged as effective treatments, allowing rapid gains in bone mineral density (BMD) and reducing fracture risk...Effective treatments, such as anabolic agents, are key in high-risk patients, who require an 'anabolic first' approach. Sequential therapy, specifically tailored to a patient's history, can help to optimize prevention and management of fractures.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Australian clinicians' perceptions of patients with very high risk of fracture. (Pubmed Central) -  Jan 2, 2024   
    Australian clinicians' perceptions of patients with a VHR of fracture and the use of anabolic agents appear to be heavily influenced by local reimbursement criteria. The mismatch between patients deemed eligible for reimbursed anabolic therapy and those prescribed an anabolic agent suggests treatment inertia.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  The Sequential Therapy in Osteoporosis. (Pubmed Central) -  Dec 18, 2023   
    Despite the absence of fracture data substantiating the implementation of integrated anabolic/antiresorptive pharmacotherapy, the incorporation of denosumab and teriparatide presents a potential avenue worthy of consideration for individuals at a heightened vulnerability to fragility fractures. A judiciously implemented sequential treatment strategy in osteoporosis offers a flexible and tailored approach to address diverse clinical scenarios, optimizing fracture prevention and patient outcomes.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal, Real-world evidence, Real-world:  Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. (Pubmed Central) -  Dec 12, 2023   
    A judiciously implemented sequential treatment strategy in osteoporosis offers a flexible and tailored approach to address diverse clinical scenarios, optimizing fracture prevention and patient outcomes. This large-scale, multicenter chart review provides clinically relevant insights into the profiles of patients initiating romosozumab, effectiveness of real-world romosozumab use, and sequential therapy in Japanese patients at high risk of fracture.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Buds of new bone formation within the femoral head of hip fracture patients coincide with zones of low osteocyte sclerostin. (Pubmed Central) -  Dec 4, 2023   
    Romosozumab treatment reduces the rate of hip fractures and increases hip bone density, increasing bone formation by inhibiting sclerostin protein...FMiS density correlated with greater amount, thickness, number and connectivity of trabeculae (bone volume BV/TV, r?=?0.65, p?<?0.0001; bone surface BS/TV, r?=?0.47, p?<?0.01; trabecular thickness Tb.Th, r?=?0.55, p?<?0.001; trabecular number Tb.N, r?=?0.47, p?<?0.01; and connectivity density Conn.D, r?=?0.40, p?<?0.05) and lower trabecular separation (Tb.Sp, r?=?-0.56, p?<?0.001). These results demonstrate modeling-based bone formation in femoral trabeculae from patients with hip fracture as a potential therapeutic target to enhance bone structure.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Reimbursement, US reimbursement, Journal, Medicare:  The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare. (Pubmed Central) -  Nov 24, 2023   
    Compared to the pre-COVID period, the lockdown negatively impacted the continuity of romosozumab treatment among Medicare beneficiaries. Prioritizing in-time assistance for patients receiving a provider-administered parenteral therapy is critical when patients' in-person access to their provider is compromised.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Trial completion, Trial completion date:  Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users (clinicaltrials.gov) -  Nov 21, 2023   
    P4,  N=70, Completed, 
    Our findings suggest that patients who undergo elective THA might benefit from optimal preoperative diagnosis and medical management of OP. Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2023
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Enrollment open:  A Study of Romosozumab (EVENITY (clinicaltrials.gov) -  Nov 21, 2023   
    P4,  N=100, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2023 Not yet recruiting --> Recruiting